Jounce Therapeutics (NASDAQ:JNCE) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.
This table compares Jounce Therapeutics and Autolus Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
84.2% of Jounce Therapeutics shares are held by institutional investors. Comparatively, 21.2% of Autolus Therapeutics shares are held by institutional investors. 44.0% of Jounce Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Jounce Therapeutics and Autolus Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Jounce Therapeutics||$71.64 million||1.99||-$16.44 million||($0.57)||-7.65|
Autolus Therapeutics has lower revenue, but higher earnings than Jounce Therapeutics.
This is a summary of current recommendations for Jounce Therapeutics and Autolus Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Jounce Therapeutics currently has a consensus price target of $13.00, suggesting a potential upside of 198.17%. Autolus Therapeutics has a consensus price target of $37.50, suggesting a potential upside of 34.26%. Given Jounce Therapeutics’ higher probable upside, research analysts clearly believe Jounce Therapeutics is more favorable than Autolus Therapeutics.
Autolus Therapeutics beats Jounce Therapeutics on 5 of the 9 factors compared between the two stocks.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Autolus Therapeutics Company Profile
Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.